MedTrace Logo

Sphenopalatine Ganglion Block with Tx360 for Trigeminal Neuralgia

NCT06663410 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 15

Last updated 2024-10-29

No results posted yet for this study

Summary

The aim of this study was to investigate the effect of sphenopalatine ganglion (SPG) block bilaterally through a nasal device called Tx360 by delivering 0.3cc of lidocaine 2% for pain relief in patients with Trigeminal Neuralgia (TN).

Conditions

  • Trigeminal Neuralgia

Interventions

DEVICE

SPG block with the use of the Tx360 device

A SPG block was performed using the Tx360 nasal applicator according to the manufacturer's instructions bilaterally, injecting 0.3cc of lidocaine 2% into each nostril.

Sponsors & Collaborators

  • Aretaieio Hospital

    lead OTHER

Principal Investigators

  • Athanasia Tsaroucha, Assoc. Prof. · Aretaieio Hospital, National and Kapodistrian University of Athens

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-28
Primary Completion
2024-04-15
Completion
2024-04-15

Countries

  • Greece

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06663410 on ClinicalTrials.gov